Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
Purpose The AURA study ( ClinicalTrials.gov identifier: NCT01802632) included two cohorts of treatment-naïve patients to examine clinical activity and safety of osimertinib (an epidermal growth factor receptor [EGFR] -tyrosine kinase inhibitor selective for EGFR-tyrosine kinase inhibitor sensitizing...
Uloženo v:
| Vydáno v: | Journal of clinical oncology Ročník 36; číslo 9; s. 841 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
20.03.2018
|
| Témata: | |
| ISSN: | 1527-7755, 1527-7755 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Purpose The AURA study ( ClinicalTrials.gov identifier: NCT01802632) included two cohorts of treatment-naïve patients to examine clinical activity and safety of osimertinib (an epidermal growth factor receptor [EGFR] -tyrosine kinase inhibitor selective for EGFR-tyrosine kinase inhibitor sensitizing [ EGFRm] and EGFR T790M resistance mutations) as first-line treatment of EGFR-mutated advanced non-small-cell lung cancer (NSCLC). Patients and Methods Sixty treatment-naïve patients with locally advanced or metastatic EGFRm NSCLC received osimertinib 80 or 160 mg once daily (30 patients per cohort). End points included investigator-assessed objective response rate (ORR), progression-free survival (PFS), and safety evaluation. Plasma samples were collected at or after patients experienced disease progression, as defined by Response Evaluation Criteria in Solid Tumors (RECIST), to investigate osimertinib resistance mechanisms. Results At data cutoff (November 1, 2016), median follow-up was 19.1 months. Overall ORR was 67% (95% CI, 47% to 83%) in the 80-mg group, 87% (95% CI, 69% to 96%) in the 160-mg group, and 77% (95% CI, 64% to 87%) across doses. Median PFS time was 22.1 months (95% CI, 13.7 to 30.2 months) in the 80-mg group, 19.3 months (95% CI, 13.7 to 26.0 months) in the 160-mg group, and 20.5 months (95% CI, 15.0 to 26.1 months) across doses. Of 38 patients with postprogression plasma samples, 50% had no detectable circulating tumor DNA. Nine of 19 patients had putative resistance mechanisms, including amplification of MET (n = 1); amplification of EGFR and KRAS (n = 1); MEK1, KRAS, or PIK3CA mutation (n = 1 each); EGFR C797S mutation (n = 2); JAK2 mutation (n = 1); and HER2 exon 20 insertion (n = 1). Acquired EGFR T790M was not detected. Conclusion Osimertinib demonstrated a robust ORR and prolonged PFS in treatment-naïve patients with EGFRm advanced NSCLC. There was no evidence of acquired EGFR T790M mutation in postprogression plasma samples. |
|---|---|
| AbstractList | Purpose The AURA study ( ClinicalTrials.gov identifier: NCT01802632) included two cohorts of treatment-naïve patients to examine clinical activity and safety of osimertinib (an epidermal growth factor receptor [EGFR] -tyrosine kinase inhibitor selective for EGFR-tyrosine kinase inhibitor sensitizing [ EGFRm] and EGFR T790M resistance mutations) as first-line treatment of EGFR-mutated advanced non-small-cell lung cancer (NSCLC). Patients and Methods Sixty treatment-naïve patients with locally advanced or metastatic EGFRm NSCLC received osimertinib 80 or 160 mg once daily (30 patients per cohort). End points included investigator-assessed objective response rate (ORR), progression-free survival (PFS), and safety evaluation. Plasma samples were collected at or after patients experienced disease progression, as defined by Response Evaluation Criteria in Solid Tumors (RECIST), to investigate osimertinib resistance mechanisms. Results At data cutoff (November 1, 2016), median follow-up was 19.1 months. Overall ORR was 67% (95% CI, 47% to 83%) in the 80-mg group, 87% (95% CI, 69% to 96%) in the 160-mg group, and 77% (95% CI, 64% to 87%) across doses. Median PFS time was 22.1 months (95% CI, 13.7 to 30.2 months) in the 80-mg group, 19.3 months (95% CI, 13.7 to 26.0 months) in the 160-mg group, and 20.5 months (95% CI, 15.0 to 26.1 months) across doses. Of 38 patients with postprogression plasma samples, 50% had no detectable circulating tumor DNA. Nine of 19 patients had putative resistance mechanisms, including amplification of MET (n = 1); amplification of EGFR and KRAS (n = 1); MEK1, KRAS, or PIK3CA mutation (n = 1 each); EGFR C797S mutation (n = 2); JAK2 mutation (n = 1); and HER2 exon 20 insertion (n = 1). Acquired EGFR T790M was not detected. Conclusion Osimertinib demonstrated a robust ORR and prolonged PFS in treatment-naïve patients with EGFRm advanced NSCLC. There was no evidence of acquired EGFR T790M mutation in postprogression plasma samples.Purpose The AURA study ( ClinicalTrials.gov identifier: NCT01802632) included two cohorts of treatment-naïve patients to examine clinical activity and safety of osimertinib (an epidermal growth factor receptor [EGFR] -tyrosine kinase inhibitor selective for EGFR-tyrosine kinase inhibitor sensitizing [ EGFRm] and EGFR T790M resistance mutations) as first-line treatment of EGFR-mutated advanced non-small-cell lung cancer (NSCLC). Patients and Methods Sixty treatment-naïve patients with locally advanced or metastatic EGFRm NSCLC received osimertinib 80 or 160 mg once daily (30 patients per cohort). End points included investigator-assessed objective response rate (ORR), progression-free survival (PFS), and safety evaluation. Plasma samples were collected at or after patients experienced disease progression, as defined by Response Evaluation Criteria in Solid Tumors (RECIST), to investigate osimertinib resistance mechanisms. Results At data cutoff (November 1, 2016), median follow-up was 19.1 months. Overall ORR was 67% (95% CI, 47% to 83%) in the 80-mg group, 87% (95% CI, 69% to 96%) in the 160-mg group, and 77% (95% CI, 64% to 87%) across doses. Median PFS time was 22.1 months (95% CI, 13.7 to 30.2 months) in the 80-mg group, 19.3 months (95% CI, 13.7 to 26.0 months) in the 160-mg group, and 20.5 months (95% CI, 15.0 to 26.1 months) across doses. Of 38 patients with postprogression plasma samples, 50% had no detectable circulating tumor DNA. Nine of 19 patients had putative resistance mechanisms, including amplification of MET (n = 1); amplification of EGFR and KRAS (n = 1); MEK1, KRAS, or PIK3CA mutation (n = 1 each); EGFR C797S mutation (n = 2); JAK2 mutation (n = 1); and HER2 exon 20 insertion (n = 1). Acquired EGFR T790M was not detected. Conclusion Osimertinib demonstrated a robust ORR and prolonged PFS in treatment-naïve patients with EGFRm advanced NSCLC. There was no evidence of acquired EGFR T790M mutation in postprogression plasma samples. Purpose The AURA study ( ClinicalTrials.gov identifier: NCT01802632) included two cohorts of treatment-naïve patients to examine clinical activity and safety of osimertinib (an epidermal growth factor receptor [EGFR] -tyrosine kinase inhibitor selective for EGFR-tyrosine kinase inhibitor sensitizing [ EGFRm] and EGFR T790M resistance mutations) as first-line treatment of EGFR-mutated advanced non-small-cell lung cancer (NSCLC). Patients and Methods Sixty treatment-naïve patients with locally advanced or metastatic EGFRm NSCLC received osimertinib 80 or 160 mg once daily (30 patients per cohort). End points included investigator-assessed objective response rate (ORR), progression-free survival (PFS), and safety evaluation. Plasma samples were collected at or after patients experienced disease progression, as defined by Response Evaluation Criteria in Solid Tumors (RECIST), to investigate osimertinib resistance mechanisms. Results At data cutoff (November 1, 2016), median follow-up was 19.1 months. Overall ORR was 67% (95% CI, 47% to 83%) in the 80-mg group, 87% (95% CI, 69% to 96%) in the 160-mg group, and 77% (95% CI, 64% to 87%) across doses. Median PFS time was 22.1 months (95% CI, 13.7 to 30.2 months) in the 80-mg group, 19.3 months (95% CI, 13.7 to 26.0 months) in the 160-mg group, and 20.5 months (95% CI, 15.0 to 26.1 months) across doses. Of 38 patients with postprogression plasma samples, 50% had no detectable circulating tumor DNA. Nine of 19 patients had putative resistance mechanisms, including amplification of MET (n = 1); amplification of EGFR and KRAS (n = 1); MEK1, KRAS, or PIK3CA mutation (n = 1 each); EGFR C797S mutation (n = 2); JAK2 mutation (n = 1); and HER2 exon 20 insertion (n = 1). Acquired EGFR T790M was not detected. Conclusion Osimertinib demonstrated a robust ORR and prolonged PFS in treatment-naïve patients with EGFRm advanced NSCLC. There was no evidence of acquired EGFR T790M mutation in postprogression plasma samples. |
| Author | Ohe, Yuichiro Kurata, Takayasu John, Thomas Lee, Chee Khoon Rukazenkov, Yuri Ramalingam, Suresh S Mann, Helen Stetson, Daniel Barrett, J Carl Ghiorghiu, Serban Markovets, Aleksandra Thress, Kenneth S Jänne, Pasi A Kim, Dong-Wan Yang, James C-H Nogami, Naoyuki |
| Author_xml | – sequence: 1 givenname: Suresh S surname: Ramalingam fullname: Ramalingam, Suresh S organization: Suresh S. Ramalingam, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA; James C.-H. Yang, National Taiwan University and National Taiwan University Cancer Center, Taipei, Taiwan; Chee Khoon Lee, St George Hospital, Sydney, New South Wales; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Victoria, Australia; Takayasu Kurata, Kansai Medical University Hirakata Hospital, Osaka; Naoyuki Nogami, National Hospital Organization Shikoku Cancer Center, Matsuyama; Yuichiro Ohe, National Cancer Center Hospital East, Kashiwa-City, Japan; Dong-Wan Kim, Seoul National University Hospital, Seoul, Republic of Korea; Helen Mann, AstraZeneca, Macclesfield; Yuri Rukazenkov and Serban Ghiorghiu, AstraZeneca, Cambridge, United Kingdom; Daniel Stetson, Aleksandra Markovets, J. Carl Barrett, and Kenneth S. Thress, AstraZeneca, Waltham; and Pasi A. Jänne, Dana-Farber Cancer Institute and the Belfer Center for Applied Cancer Science, Boston, MA – sequence: 2 givenname: James C-H surname: Yang fullname: Yang, James C-H organization: Suresh S. Ramalingam, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA; James C.-H. Yang, National Taiwan University and National Taiwan University Cancer Center, Taipei, Taiwan; Chee Khoon Lee, St George Hospital, Sydney, New South Wales; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Victoria, Australia; Takayasu Kurata, Kansai Medical University Hirakata Hospital, Osaka; Naoyuki Nogami, National Hospital Organization Shikoku Cancer Center, Matsuyama; Yuichiro Ohe, National Cancer Center Hospital East, Kashiwa-City, Japan; Dong-Wan Kim, Seoul National University Hospital, Seoul, Republic of Korea; Helen Mann, AstraZeneca, Macclesfield; Yuri Rukazenkov and Serban Ghiorghiu, AstraZeneca, Cambridge, United Kingdom; Daniel Stetson, Aleksandra Markovets, J. Carl Barrett, and Kenneth S. Thress, AstraZeneca, Waltham; and Pasi A. Jänne, Dana-Farber Cancer Institute and the Belfer Center for Applied Cancer Science, Boston, MA – sequence: 3 givenname: Chee Khoon surname: Lee fullname: Lee, Chee Khoon organization: Suresh S. Ramalingam, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA; James C.-H. Yang, National Taiwan University and National Taiwan University Cancer Center, Taipei, Taiwan; Chee Khoon Lee, St George Hospital, Sydney, New South Wales; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Victoria, Australia; Takayasu Kurata, Kansai Medical University Hirakata Hospital, Osaka; Naoyuki Nogami, National Hospital Organization Shikoku Cancer Center, Matsuyama; Yuichiro Ohe, National Cancer Center Hospital East, Kashiwa-City, Japan; Dong-Wan Kim, Seoul National University Hospital, Seoul, Republic of Korea; Helen Mann, AstraZeneca, Macclesfield; Yuri Rukazenkov and Serban Ghiorghiu, AstraZeneca, Cambridge, United Kingdom; Daniel Stetson, Aleksandra Markovets, J. Carl Barrett, and Kenneth S. Thress, AstraZeneca, Waltham; and Pasi A. Jänne, Dana-Farber Cancer Institute and the Belfer Center for Applied Cancer Science, Boston, MA – sequence: 4 givenname: Takayasu surname: Kurata fullname: Kurata, Takayasu organization: Suresh S. Ramalingam, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA; James C.-H. Yang, National Taiwan University and National Taiwan University Cancer Center, Taipei, Taiwan; Chee Khoon Lee, St George Hospital, Sydney, New South Wales; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Victoria, Australia; Takayasu Kurata, Kansai Medical University Hirakata Hospital, Osaka; Naoyuki Nogami, National Hospital Organization Shikoku Cancer Center, Matsuyama; Yuichiro Ohe, National Cancer Center Hospital East, Kashiwa-City, Japan; Dong-Wan Kim, Seoul National University Hospital, Seoul, Republic of Korea; Helen Mann, AstraZeneca, Macclesfield; Yuri Rukazenkov and Serban Ghiorghiu, AstraZeneca, Cambridge, United Kingdom; Daniel Stetson, Aleksandra Markovets, J. Carl Barrett, and Kenneth S. Thress, AstraZeneca, Waltham; and Pasi A. Jänne, Dana-Farber Cancer Institute and the Belfer Center for Applied Cancer Science, Boston, MA – sequence: 5 givenname: Dong-Wan surname: Kim fullname: Kim, Dong-Wan organization: Suresh S. Ramalingam, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA; James C.-H. Yang, National Taiwan University and National Taiwan University Cancer Center, Taipei, Taiwan; Chee Khoon Lee, St George Hospital, Sydney, New South Wales; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Victoria, Australia; Takayasu Kurata, Kansai Medical University Hirakata Hospital, Osaka; Naoyuki Nogami, National Hospital Organization Shikoku Cancer Center, Matsuyama; Yuichiro Ohe, National Cancer Center Hospital East, Kashiwa-City, Japan; Dong-Wan Kim, Seoul National University Hospital, Seoul, Republic of Korea; Helen Mann, AstraZeneca, Macclesfield; Yuri Rukazenkov and Serban Ghiorghiu, AstraZeneca, Cambridge, United Kingdom; Daniel Stetson, Aleksandra Markovets, J. Carl Barrett, and Kenneth S. Thress, AstraZeneca, Waltham; and Pasi A. Jänne, Dana-Farber Cancer Institute and the Belfer Center for Applied Cancer Science, Boston, MA – sequence: 6 givenname: Thomas surname: John fullname: John, Thomas organization: Suresh S. Ramalingam, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA; James C.-H. Yang, National Taiwan University and National Taiwan University Cancer Center, Taipei, Taiwan; Chee Khoon Lee, St George Hospital, Sydney, New South Wales; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Victoria, Australia; Takayasu Kurata, Kansai Medical University Hirakata Hospital, Osaka; Naoyuki Nogami, National Hospital Organization Shikoku Cancer Center, Matsuyama; Yuichiro Ohe, National Cancer Center Hospital East, Kashiwa-City, Japan; Dong-Wan Kim, Seoul National University Hospital, Seoul, Republic of Korea; Helen Mann, AstraZeneca, Macclesfield; Yuri Rukazenkov and Serban Ghiorghiu, AstraZeneca, Cambridge, United Kingdom; Daniel Stetson, Aleksandra Markovets, J. Carl Barrett, and Kenneth S. Thress, AstraZeneca, Waltham; and Pasi A. Jänne, Dana-Farber Cancer Institute and the Belfer Center for Applied Cancer Science, Boston, MA – sequence: 7 givenname: Naoyuki surname: Nogami fullname: Nogami, Naoyuki organization: Suresh S. Ramalingam, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA; James C.-H. Yang, National Taiwan University and National Taiwan University Cancer Center, Taipei, Taiwan; Chee Khoon Lee, St George Hospital, Sydney, New South Wales; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Victoria, Australia; Takayasu Kurata, Kansai Medical University Hirakata Hospital, Osaka; Naoyuki Nogami, National Hospital Organization Shikoku Cancer Center, Matsuyama; Yuichiro Ohe, National Cancer Center Hospital East, Kashiwa-City, Japan; Dong-Wan Kim, Seoul National University Hospital, Seoul, Republic of Korea; Helen Mann, AstraZeneca, Macclesfield; Yuri Rukazenkov and Serban Ghiorghiu, AstraZeneca, Cambridge, United Kingdom; Daniel Stetson, Aleksandra Markovets, J. Carl Barrett, and Kenneth S. Thress, AstraZeneca, Waltham; and Pasi A. Jänne, Dana-Farber Cancer Institute and the Belfer Center for Applied Cancer Science, Boston, MA – sequence: 8 givenname: Yuichiro surname: Ohe fullname: Ohe, Yuichiro organization: Suresh S. Ramalingam, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA; James C.-H. Yang, National Taiwan University and National Taiwan University Cancer Center, Taipei, Taiwan; Chee Khoon Lee, St George Hospital, Sydney, New South Wales; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Victoria, Australia; Takayasu Kurata, Kansai Medical University Hirakata Hospital, Osaka; Naoyuki Nogami, National Hospital Organization Shikoku Cancer Center, Matsuyama; Yuichiro Ohe, National Cancer Center Hospital East, Kashiwa-City, Japan; Dong-Wan Kim, Seoul National University Hospital, Seoul, Republic of Korea; Helen Mann, AstraZeneca, Macclesfield; Yuri Rukazenkov and Serban Ghiorghiu, AstraZeneca, Cambridge, United Kingdom; Daniel Stetson, Aleksandra Markovets, J. Carl Barrett, and Kenneth S. Thress, AstraZeneca, Waltham; and Pasi A. Jänne, Dana-Farber Cancer Institute and the Belfer Center for Applied Cancer Science, Boston, MA – sequence: 9 givenname: Helen surname: Mann fullname: Mann, Helen organization: Suresh S. Ramalingam, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA; James C.-H. Yang, National Taiwan University and National Taiwan University Cancer Center, Taipei, Taiwan; Chee Khoon Lee, St George Hospital, Sydney, New South Wales; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Victoria, Australia; Takayasu Kurata, Kansai Medical University Hirakata Hospital, Osaka; Naoyuki Nogami, National Hospital Organization Shikoku Cancer Center, Matsuyama; Yuichiro Ohe, National Cancer Center Hospital East, Kashiwa-City, Japan; Dong-Wan Kim, Seoul National University Hospital, Seoul, Republic of Korea; Helen Mann, AstraZeneca, Macclesfield; Yuri Rukazenkov and Serban Ghiorghiu, AstraZeneca, Cambridge, United Kingdom; Daniel Stetson, Aleksandra Markovets, J. Carl Barrett, and Kenneth S. Thress, AstraZeneca, Waltham; and Pasi A. Jänne, Dana-Farber Cancer Institute and the Belfer Center for Applied Cancer Science, Boston, MA – sequence: 10 givenname: Yuri surname: Rukazenkov fullname: Rukazenkov, Yuri organization: Suresh S. Ramalingam, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA; James C.-H. Yang, National Taiwan University and National Taiwan University Cancer Center, Taipei, Taiwan; Chee Khoon Lee, St George Hospital, Sydney, New South Wales; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Victoria, Australia; Takayasu Kurata, Kansai Medical University Hirakata Hospital, Osaka; Naoyuki Nogami, National Hospital Organization Shikoku Cancer Center, Matsuyama; Yuichiro Ohe, National Cancer Center Hospital East, Kashiwa-City, Japan; Dong-Wan Kim, Seoul National University Hospital, Seoul, Republic of Korea; Helen Mann, AstraZeneca, Macclesfield; Yuri Rukazenkov and Serban Ghiorghiu, AstraZeneca, Cambridge, United Kingdom; Daniel Stetson, Aleksandra Markovets, J. Carl Barrett, and Kenneth S. Thress, AstraZeneca, Waltham; and Pasi A. Jänne, Dana-Farber Cancer Institute and the Belfer Center for Applied Cancer Science, Boston, MA – sequence: 11 givenname: Serban surname: Ghiorghiu fullname: Ghiorghiu, Serban organization: Suresh S. Ramalingam, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA; James C.-H. Yang, National Taiwan University and National Taiwan University Cancer Center, Taipei, Taiwan; Chee Khoon Lee, St George Hospital, Sydney, New South Wales; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Victoria, Australia; Takayasu Kurata, Kansai Medical University Hirakata Hospital, Osaka; Naoyuki Nogami, National Hospital Organization Shikoku Cancer Center, Matsuyama; Yuichiro Ohe, National Cancer Center Hospital East, Kashiwa-City, Japan; Dong-Wan Kim, Seoul National University Hospital, Seoul, Republic of Korea; Helen Mann, AstraZeneca, Macclesfield; Yuri Rukazenkov and Serban Ghiorghiu, AstraZeneca, Cambridge, United Kingdom; Daniel Stetson, Aleksandra Markovets, J. Carl Barrett, and Kenneth S. Thress, AstraZeneca, Waltham; and Pasi A. Jänne, Dana-Farber Cancer Institute and the Belfer Center for Applied Cancer Science, Boston, MA – sequence: 12 givenname: Daniel surname: Stetson fullname: Stetson, Daniel organization: Suresh S. Ramalingam, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA; James C.-H. Yang, National Taiwan University and National Taiwan University Cancer Center, Taipei, Taiwan; Chee Khoon Lee, St George Hospital, Sydney, New South Wales; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Victoria, Australia; Takayasu Kurata, Kansai Medical University Hirakata Hospital, Osaka; Naoyuki Nogami, National Hospital Organization Shikoku Cancer Center, Matsuyama; Yuichiro Ohe, National Cancer Center Hospital East, Kashiwa-City, Japan; Dong-Wan Kim, Seoul National University Hospital, Seoul, Republic of Korea; Helen Mann, AstraZeneca, Macclesfield; Yuri Rukazenkov and Serban Ghiorghiu, AstraZeneca, Cambridge, United Kingdom; Daniel Stetson, Aleksandra Markovets, J. Carl Barrett, and Kenneth S. Thress, AstraZeneca, Waltham; and Pasi A. Jänne, Dana-Farber Cancer Institute and the Belfer Center for Applied Cancer Science, Boston, MA – sequence: 13 givenname: Aleksandra surname: Markovets fullname: Markovets, Aleksandra organization: Suresh S. Ramalingam, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA; James C.-H. Yang, National Taiwan University and National Taiwan University Cancer Center, Taipei, Taiwan; Chee Khoon Lee, St George Hospital, Sydney, New South Wales; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Victoria, Australia; Takayasu Kurata, Kansai Medical University Hirakata Hospital, Osaka; Naoyuki Nogami, National Hospital Organization Shikoku Cancer Center, Matsuyama; Yuichiro Ohe, National Cancer Center Hospital East, Kashiwa-City, Japan; Dong-Wan Kim, Seoul National University Hospital, Seoul, Republic of Korea; Helen Mann, AstraZeneca, Macclesfield; Yuri Rukazenkov and Serban Ghiorghiu, AstraZeneca, Cambridge, United Kingdom; Daniel Stetson, Aleksandra Markovets, J. Carl Barrett, and Kenneth S. Thress, AstraZeneca, Waltham; and Pasi A. Jänne, Dana-Farber Cancer Institute and the Belfer Center for Applied Cancer Science, Boston, MA – sequence: 14 givenname: J Carl surname: Barrett fullname: Barrett, J Carl organization: Suresh S. Ramalingam, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA; James C.-H. Yang, National Taiwan University and National Taiwan University Cancer Center, Taipei, Taiwan; Chee Khoon Lee, St George Hospital, Sydney, New South Wales; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Victoria, Australia; Takayasu Kurata, Kansai Medical University Hirakata Hospital, Osaka; Naoyuki Nogami, National Hospital Organization Shikoku Cancer Center, Matsuyama; Yuichiro Ohe, National Cancer Center Hospital East, Kashiwa-City, Japan; Dong-Wan Kim, Seoul National University Hospital, Seoul, Republic of Korea; Helen Mann, AstraZeneca, Macclesfield; Yuri Rukazenkov and Serban Ghiorghiu, AstraZeneca, Cambridge, United Kingdom; Daniel Stetson, Aleksandra Markovets, J. Carl Barrett, and Kenneth S. Thress, AstraZeneca, Waltham; and Pasi A. Jänne, Dana-Farber Cancer Institute and the Belfer Center for Applied Cancer Science, Boston, MA – sequence: 15 givenname: Kenneth S surname: Thress fullname: Thress, Kenneth S organization: Suresh S. Ramalingam, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA; James C.-H. Yang, National Taiwan University and National Taiwan University Cancer Center, Taipei, Taiwan; Chee Khoon Lee, St George Hospital, Sydney, New South Wales; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Victoria, Australia; Takayasu Kurata, Kansai Medical University Hirakata Hospital, Osaka; Naoyuki Nogami, National Hospital Organization Shikoku Cancer Center, Matsuyama; Yuichiro Ohe, National Cancer Center Hospital East, Kashiwa-City, Japan; Dong-Wan Kim, Seoul National University Hospital, Seoul, Republic of Korea; Helen Mann, AstraZeneca, Macclesfield; Yuri Rukazenkov and Serban Ghiorghiu, AstraZeneca, Cambridge, United Kingdom; Daniel Stetson, Aleksandra Markovets, J. Carl Barrett, and Kenneth S. Thress, AstraZeneca, Waltham; and Pasi A. Jänne, Dana-Farber Cancer Institute and the Belfer Center for Applied Cancer Science, Boston, MA – sequence: 16 givenname: Pasi A surname: Jänne fullname: Jänne, Pasi A organization: Suresh S. Ramalingam, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA; James C.-H. Yang, National Taiwan University and National Taiwan University Cancer Center, Taipei, Taiwan; Chee Khoon Lee, St George Hospital, Sydney, New South Wales; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Victoria, Australia; Takayasu Kurata, Kansai Medical University Hirakata Hospital, Osaka; Naoyuki Nogami, National Hospital Organization Shikoku Cancer Center, Matsuyama; Yuichiro Ohe, National Cancer Center Hospital East, Kashiwa-City, Japan; Dong-Wan Kim, Seoul National University Hospital, Seoul, Republic of Korea; Helen Mann, AstraZeneca, Macclesfield; Yuri Rukazenkov and Serban Ghiorghiu, AstraZeneca, Cambridge, United Kingdom; Daniel Stetson, Aleksandra Markovets, J. Carl Barrett, and Kenneth S. Thress, AstraZeneca, Waltham; and Pasi A. Jänne, Dana-Farber Cancer Institute and the Belfer Center for Applied Cancer Science, Boston, MA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28841389$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkEtPwzAQhC1URB9w54R85JJgO3EcH6uoLaBAEZRzZCcbZJQ4JXYq9d8TRJE4zWjn02p35mhiOwsIXVMSUkbI3WO2DRmhIhRxKLhIztCMciYCITif_PNTNHfukxAapxG_QFOWpjGNUjlDautMC7031mi8dHhteueD3FjAux6Ub8F63NV4tVm_4qfBK286G7x0znhzALysDsqWUOHncfrWqqYJMmganA_2A2c_UX-JzmvVOLg66QK9r1e77D7It5uHbJkHZZRwH4BQLJYkqVkUpZWqBWOUJVLzCqSsVaU0JTqVia4SUiZUS800UTXUMuKlkBFboNvfvfu--xrA-aI1rhyPURa6wRV0ZFJOxrdH9OaEDrqFqtj3plX9sfirhX0D-7plzA |
| CitedBy_id | crossref_primary_10_1016_j_critrevonc_2021_103225 crossref_primary_10_1148_radiol_2019190173 crossref_primary_10_1002_1878_0261_12682 crossref_primary_10_1016_j_cllc_2020_06_015 crossref_primary_10_1007_s10198_020_01186_9 crossref_primary_10_3389_fimmu_2019_02250 crossref_primary_10_1177_0004563218798401 crossref_primary_10_1002_adhm_202100078 crossref_primary_10_1186_s12943_021_01307_9 crossref_primary_10_1183_20734735_0035_2024 crossref_primary_10_1016_j_jmb_2022_167626 crossref_primary_10_1002_mco2_105 crossref_primary_10_1158_1541_7786_MCR_18_0628 crossref_primary_10_1002_cncr_31289 crossref_primary_10_1016_S2213_2600_17_30479_4 crossref_primary_10_1111_bcp_16199 crossref_primary_10_1007_s00432_022_04048_4 crossref_primary_10_3390_cancers15205009 crossref_primary_10_1016_j_critrevonc_2021_103454 crossref_primary_10_1016_j_phymed_2020_153189 crossref_primary_10_1016_j_jtho_2017_09_1953 crossref_primary_10_1038_s41467_025_61788_w crossref_primary_10_1111_cas_14593 crossref_primary_10_1002_prp2_70098 crossref_primary_10_3390_cancers12051196 crossref_primary_10_1016_j_resinv_2021_03_010 crossref_primary_10_1159_000533826 crossref_primary_10_1016_j_annonc_2022_02_003 crossref_primary_10_1016_j_lungcan_2021_08_001 crossref_primary_10_3389_fonc_2023_1047644 crossref_primary_10_3390_ijms25136961 crossref_primary_10_3892_ol_2019_10265 crossref_primary_10_2217_fon_2018_0626 crossref_primary_10_1097_COC_0000000000001047 crossref_primary_10_1177_17588359241234504 crossref_primary_10_1016_j_jtcvs_2020_04_096 crossref_primary_10_1016_j_ejmech_2021_113173 crossref_primary_10_1016_j_lungcan_2018_01_006 crossref_primary_10_1002_ijc_32015 crossref_primary_10_3390_curroncol32040191 crossref_primary_10_1053_j_seminoncol_2019_08_004 crossref_primary_10_1016_j_jmoldx_2019_06_010 crossref_primary_10_1016_j_jtho_2022_11_009 crossref_primary_10_1016_j_cllc_2022_06_001 crossref_primary_10_1146_annurev_med_051718_013524 crossref_primary_10_3390_cells11203200 crossref_primary_10_1016_j_lungcan_2025_108747 crossref_primary_10_3390_cancers15143561 crossref_primary_10_1016_j_omtn_2020_09_015 crossref_primary_10_1016_j_lungcan_2020_06_003 crossref_primary_10_1016_j_lungcan_2020_04_032 crossref_primary_10_1111_1759_7714_14288 crossref_primary_10_1016_j_cllc_2019_02_016 crossref_primary_10_1186_s12967_025_06874_9 crossref_primary_10_1016_j_ebiom_2022_104200 crossref_primary_10_1016_j_labinv_2024_102094 crossref_primary_10_1007_s12094_019_02204_w crossref_primary_10_1186_s12885_022_10390_0 crossref_primary_10_3390_ijms20010146 crossref_primary_10_1007_s12033_024_01127_4 crossref_primary_10_3389_fonc_2018_00094 crossref_primary_10_1016_j_ejca_2024_114182 crossref_primary_10_2217_fon_2018_0097 crossref_primary_10_1097_MD_0000000000011569 crossref_primary_10_1158_1078_0432_CCR_19_3563 crossref_primary_10_2217_fon_2018_0095 crossref_primary_10_3389_fonc_2022_937282 crossref_primary_10_3390_pharmaceutics14091844 crossref_primary_10_3892_ol_2017_7679 crossref_primary_10_3389_fphar_2022_1109822 crossref_primary_10_1007_s11684_022_0934_1 crossref_primary_10_1002_advs_202411479 crossref_primary_10_1016_j_rmcr_2022_101682 crossref_primary_10_1038_s41598_022_12995_8 crossref_primary_10_1007_s40267_018_0536_9 crossref_primary_10_1016_j_jtho_2025_07_117 crossref_primary_10_1158_1078_0432_CCR_20_4084 crossref_primary_10_15252_emmm_202013144 crossref_primary_10_1371_journal_pone_0236580 crossref_primary_10_1002_prp2_528 crossref_primary_10_1016_j_bbcan_2021_188645 crossref_primary_10_1111_1759_7714_14272 crossref_primary_10_3389_fonc_2023_1241402 crossref_primary_10_3390_cancers12092394 crossref_primary_10_3390_cancers14143337 crossref_primary_10_1016_j_ctrv_2020_101996 crossref_primary_10_1038_s41571_018_0081_4 crossref_primary_10_1038_s41388_018_0482_y crossref_primary_10_1016_S2213_2600_17_30480_0 crossref_primary_10_1007_s00520_024_08551_x crossref_primary_10_3390_jcm12041438 crossref_primary_10_3390_ijms241914742 crossref_primary_10_1016_j_phrs_2019_03_006 crossref_primary_10_2217_fon_2019_0052 crossref_primary_10_2217_fon_2018_0711 crossref_primary_10_1158_2159_8290_CD_20_1385 crossref_primary_10_1016_j_tranon_2019_02_006 crossref_primary_10_1038_s41416_019_0573_8 crossref_primary_10_1073_pnas_2417144121 crossref_primary_10_1016_j_apsusc_2024_161033 crossref_primary_10_1002_ange_201802416 crossref_primary_10_1007_s11051_025_06233_1 crossref_primary_10_1016_j_xcrm_2025_102121 crossref_primary_10_1080_1061186X_2020_1737934 crossref_primary_10_1016_j_drup_2025_101245 crossref_primary_10_1016_j_jtho_2024_07_008 crossref_primary_10_1001_jama_2019_11058 crossref_primary_10_1097_MD_0000000000011081 crossref_primary_10_3390_cancers14143323 crossref_primary_10_1016_S2213_2600_18_30264_9 crossref_primary_10_4103_gjtm_gjtm_88_21 crossref_primary_10_4103_ijc_IJC_449_19 crossref_primary_10_2147_OTT_S254464 crossref_primary_10_1097_FTD_0000000000001355 crossref_primary_10_3389_fonc_2023_1252652 crossref_primary_10_3390_ijms242115684 crossref_primary_10_1158_1541_7786_MCR_19_0419 crossref_primary_10_3390_cancers13112748 crossref_primary_10_1016_j_jtho_2019_04_013 crossref_primary_10_1111_1759_7714_14836 crossref_primary_10_1158_2159_8290_CD_18_0903 crossref_primary_10_1080_17425255_2017_1401064 crossref_primary_10_1016_j_cllc_2019_09_007 crossref_primary_10_2217_fon_2020_0303 crossref_primary_10_3389_fonc_2023_1064487 crossref_primary_10_1002_1878_0261_12645 crossref_primary_10_1016_j_clinthera_2018_12_007 crossref_primary_10_1038_s41598_019_56356_4 crossref_primary_10_1002_anie_201802416 crossref_primary_10_1002_onco_13951 crossref_primary_10_3390_pharmaceutics16070890 crossref_primary_10_1002_cac2_12327 crossref_primary_10_1007_s12325_019_00917_6 crossref_primary_10_1016_j_critrevonc_2024_104295 crossref_primary_10_1111_1759_7714_13839 crossref_primary_10_1038_s41598_022_10598_x crossref_primary_10_1186_s12890_021_01539_x crossref_primary_10_1186_s13045_022_01391_4 crossref_primary_10_1200_JCO_24_01061 crossref_primary_10_1093_jjco_hyaa067 crossref_primary_10_3390_cells13050436 crossref_primary_10_2217_fon_2018_0736 crossref_primary_10_1016_j_jbc_2025_110305 crossref_primary_10_1158_1078_0432_CCR_18_2906 crossref_primary_10_3389_fphar_2019_00732 crossref_primary_10_1038_s41467_018_07078_0 crossref_primary_10_3390_ijms18112420 crossref_primary_10_1080_17476348_2020_1746646 crossref_primary_10_1186_s13045_019_0759_9 crossref_primary_10_1016_j_jaip_2024_10_027 crossref_primary_10_1080_14737140_2019_1596030 crossref_primary_10_1007_s11912_020_00909_8 crossref_primary_10_1016_j_jep_2025_120120 crossref_primary_10_1016_j_pathol_2023_11_006 crossref_primary_10_1038_s41591_023_02554_7 crossref_primary_10_1007_s00595_018_1659_2 crossref_primary_10_1200_JCO_18_02037 crossref_primary_10_1634_theoncologist_2019_0158 crossref_primary_10_1080_17425247_2019_1598374 crossref_primary_10_1016_j_bbcan_2020_188363 crossref_primary_10_1016_j_compbiolchem_2025_108669 crossref_primary_10_1186_s12943_020_01202_9 crossref_primary_10_3390_jcm9061884 crossref_primary_10_7759_cureus_22372 crossref_primary_10_1016_j_cllc_2019_05_002 crossref_primary_10_3390_jmp2030018 crossref_primary_10_1002_advs_202101999 crossref_primary_10_1158_1078_0432_CCR_23_2951 crossref_primary_10_1159_000540867 crossref_primary_10_1007_s00432_023_04726_x crossref_primary_10_1007_s10147_019_01431_z crossref_primary_10_1016_j_jtho_2018_03_013 crossref_primary_10_1186_s12885_023_10637_4 crossref_primary_10_1177_1758835919836374 crossref_primary_10_3390_cells13211785 crossref_primary_10_26599_1671_5411_2023_03_009 crossref_primary_10_2217_fon_2017_0636 crossref_primary_10_1016_j_clinsp_2024_100407 crossref_primary_10_1016_j_jpba_2023_115233 crossref_primary_10_1186_s10020_019_0082_5 crossref_primary_10_1016_j_lungcan_2019_09_019 crossref_primary_10_1016_j_lungcan_2019_09_017 crossref_primary_10_1186_s13045_019_0731_8 crossref_primary_10_3389_fimmu_2023_1077203 crossref_primary_10_1111_1759_7714_13817 crossref_primary_10_3390_ijms25020807 crossref_primary_10_1038_s41598_024_59526_1 crossref_primary_10_1002_cncr_32655 crossref_primary_10_1007_s11523_018_0554_5 crossref_primary_10_1038_s41598_023_50568_5 crossref_primary_10_1016_j_tips_2019_10_004 crossref_primary_10_1136_jclinpath_2019_205863 crossref_primary_10_1002_mc_23458 crossref_primary_10_1016_j_lungcan_2020_01_009 crossref_primary_10_1038_s41467_023_35961_y crossref_primary_10_1080_10408363_2024_2302116 crossref_primary_10_1158_1078_0432_CCR_18_0991 crossref_primary_10_1016_j_jtho_2024_08_023 crossref_primary_10_3390_biom11050618 crossref_primary_10_1111_1759_7714_13154 crossref_primary_10_1007_s12032_022_01744_6 crossref_primary_10_1016_j_jtho_2021_06_013 crossref_primary_10_1016_j_tranon_2019_01_007 crossref_primary_10_1039_D4QI03025G crossref_primary_10_1002_rcr2_759 crossref_primary_10_1158_1078_0432_CCR_19_3064 crossref_primary_10_1080_13543776_2019_1624720 crossref_primary_10_1007_s12254_017_0369_6 crossref_primary_10_1016_j_jtocrr_2020_100107 crossref_primary_10_1016_j_lungcan_2018_04_024 crossref_primary_10_1016_j_procbio_2021_02_004 crossref_primary_10_1016_j_dmpk_2020_07_002 crossref_primary_10_1073_pnas_1819430116 crossref_primary_10_3892_ol_2020_11524 crossref_primary_10_1007_s10405_019_0232_z crossref_primary_10_1080_14656566_2021_1888928 crossref_primary_10_1111_1759_7714_13941 crossref_primary_10_1016_j_ctrv_2022_102354 crossref_primary_10_2217_fon_2020_0188 crossref_primary_10_1016_j_semcancer_2022_03_013 crossref_primary_10_1161_CIRCRESAHA_121_318223 crossref_primary_10_3390_pharmaceutics17070825 crossref_primary_10_2217_pgs_2018_0038 crossref_primary_10_1002_cam4_2603 crossref_primary_10_1038_s41571_025_01011_3 crossref_primary_10_1109_ACCESS_2019_2918294 crossref_primary_10_1002_cnr2_70330 crossref_primary_10_1016_j_pharmthera_2018_08_007 crossref_primary_10_1007_s11523_018_0568_z crossref_primary_10_2147_OTT_S312820 crossref_primary_10_1200_JCO_24_02624 crossref_primary_10_1016_j_jtho_2025_06_028 crossref_primary_10_1634_theoncologist_2019_0003 crossref_primary_10_1002_cncr_32996 crossref_primary_10_1158_0008_5472_CAN_19_3819 crossref_primary_10_3390_cancers13225639 crossref_primary_10_1371_journal_pone_0228188 crossref_primary_10_3390_genes10110926 crossref_primary_10_1016_j_drup_2025_101266 crossref_primary_10_2217_fon_2020_0854 crossref_primary_10_3390_diagnostics15080948 crossref_primary_10_3389_fonc_2021_659380 crossref_primary_10_1186_s13046_019_1240_x crossref_primary_10_1002_ijc_32097 crossref_primary_10_4103_ijc_IJC_50_21 crossref_primary_10_1111_ajco_13550 crossref_primary_10_7554_eLife_33718 crossref_primary_10_1016_j_jtocrr_2021_100191 crossref_primary_10_1016_j_jtho_2018_07_001 crossref_primary_10_1097_MD_0000000000017705 crossref_primary_10_3389_fphar_2022_833099 crossref_primary_10_3892_ijo_2021_5270 crossref_primary_10_1016_j_ctarc_2022_100524 crossref_primary_10_1016_j_critrevonc_2018_01_013 crossref_primary_10_1016_j_lungcan_2022_05_011 crossref_primary_10_1016_j_jtho_2019_09_006 crossref_primary_10_1097_PAP_0000000000000206 crossref_primary_10_1186_s11658_022_00348_2 crossref_primary_10_1097_CM9_0000000000001097 crossref_primary_10_1002_cncr_32744 crossref_primary_10_1080_10942912_2023_2246678 crossref_primary_10_1016_j_ejca_2022_05_023 crossref_primary_10_3390_cancers11070923 crossref_primary_10_3390_cancers13061238 crossref_primary_10_3390_ijms231810415 crossref_primary_10_1158_1078_0432_CCR_18_3829 crossref_primary_10_1038_s42003_023_04889_w crossref_primary_10_1016_j_eururo_2024_09_012 crossref_primary_10_3390_cancers17071237 crossref_primary_10_1038_s43018_022_00351_8 crossref_primary_10_1186_s13256_021_02748_y crossref_primary_10_1016_j_tranon_2020_100961 crossref_primary_10_1038_s41597_024_04169_0 crossref_primary_10_2147_LCTT_S293902 crossref_primary_10_3389_fonc_2022_853501 crossref_primary_10_1124_dmd_122_001019 crossref_primary_10_2217_fon_2019_0324 crossref_primary_10_1016_j_lungcan_2023_107233 crossref_primary_10_1056_NEJMoa1713137 crossref_primary_10_1038_s41388_022_02438_z crossref_primary_10_1002_rcr2_1131 crossref_primary_10_1016_j_semcancer_2022_04_002 crossref_primary_10_1039_C8RA10224D crossref_primary_10_1080_14728214_2018_1558203 crossref_primary_10_1016_j_bbcan_2024_189108 crossref_primary_10_3390_diagnostics10020114 crossref_primary_10_5348_101303Z01WA2022CR crossref_primary_10_1093_jjco_hyaf013 crossref_primary_10_1016_j_jtho_2023_07_007 crossref_primary_10_1038_s41571_018_0074_3 crossref_primary_10_3390_ijms26072957 crossref_primary_10_1186_s12890_022_02226_1 crossref_primary_10_1038_s41571_018_0115_y crossref_primary_10_1186_s12885_021_08581_2 crossref_primary_10_1016_j_cllc_2020_05_023 crossref_primary_10_1016_j_lungcan_2022_04_004 crossref_primary_10_1158_1078_0432_CCR_18_0304 crossref_primary_10_3390_genes14101906 crossref_primary_10_1038_s41401_020_0443_1 crossref_primary_10_3389_pore_2024_1611733 crossref_primary_10_3390_cancers15112998 crossref_primary_10_1007_s11523_023_00955_9 crossref_primary_10_1080_14737140_2021_1851200 crossref_primary_10_1183_16000617_0294_2020 crossref_primary_10_1016_j_cllc_2019_07_010 crossref_primary_10_3390_cancers11030366 crossref_primary_10_1007_s10616_024_00673_8 crossref_primary_10_3390_ijms241713077 crossref_primary_10_3390_ijms26104865 crossref_primary_10_1007_s13665_018_0204_5 crossref_primary_10_1007_s11523_021_00839_w crossref_primary_10_3390_cancers9110154 crossref_primary_10_1056_NEJMe1714580 crossref_primary_10_1038_s41388_020_01510_w crossref_primary_10_1038_s43856_025_01054_8 crossref_primary_10_1016_j_bbamcr_2021_119144 crossref_primary_10_1016_j_cllc_2024_06_003 crossref_primary_10_1016_j_molstruc_2025_142326 crossref_primary_10_1158_1078_0432_CCR_22_3497 crossref_primary_10_3390_pharmaceutics15122777 crossref_primary_10_1016_j_lungcan_2020_11_027 crossref_primary_10_1016_j_jtho_2018_04_005 crossref_primary_10_1016_j_actbio_2021_05_018 crossref_primary_10_1016_j_ijrobp_2025_01_002 crossref_primary_10_1177_0300060520928793 crossref_primary_10_1186_s40164_019_0148_7 crossref_primary_10_1016_j_annonc_2023_02_012 crossref_primary_10_1007_s40487_022_00190_8 crossref_primary_10_1016_j_lungcan_2020_12_039 crossref_primary_10_3390_cancers10080248 crossref_primary_10_1016_j_ejca_2021_01_052 crossref_primary_10_1002_med_21700 crossref_primary_10_1016_j_ctrv_2023_102557 crossref_primary_10_1007_s11523_019_00652_6 crossref_primary_10_1016_j_jtocrr_2022_100456 crossref_primary_10_1002_ctm2_70281 crossref_primary_10_1016_j_lungcan_2023_107385 crossref_primary_10_1016_j_phrs_2018_11_014 crossref_primary_10_1158_1541_7786_MCR_21_0038 crossref_primary_10_1016_j_cllc_2020_09_023 crossref_primary_10_1016_j_cej_2025_161305 crossref_primary_10_1016_j_lungcan_2019_10_013 crossref_primary_10_1016_j_biopha_2022_113959 crossref_primary_10_2147_LCTT_S517580 crossref_primary_10_1158_1078_0432_CCR_20_1690 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1200/JCO.2017.74.7576 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1527-7755 |
| ExternalDocumentID | 28841389 |
| Genre | Clinical Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- .55 0R~ 18M 2WC 34G 39C 4.4 53G 5GY 5RE 8F7 AAQQT AARDX AAWTL AAYEP AAYOK ABJNI ABOCM ACGFO ACGFS ACGUR ADBBV AEGXH AENEX AIAGR ALMA_UNASSIGNED_HOLDINGS AWKKM BAWUL BYPQX C45 CGR CS3 CUY CVF DIK EBS ECM EIF EJD F5P F9R FBNNL FD8 GX1 H13 HZ~ IH2 K-O KQ8 L7B LSO MJL N9A NPM O9- OK1 OVD OWW P2P QTD R1G RHI RLZ RUC SJN SV3 TEORI TR2 TWZ UDS VVN WH7 X7M YCJ YFH YQY 7X8 ABBLC |
| ID | FETCH-LOGICAL-c365t-e7a24906f2338daf7221269b5de99fadab10b896bd60c61b9b2b0afef935c7932 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 440 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000429062700003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1527-7755 |
| IngestDate | Wed Oct 01 14:19:08 EDT 2025 Thu Jan 02 22:54:39 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c365t-e7a24906f2338daf7221269b5de99fadab10b896bd60c61b9b2b0afef935c7932 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| PMID | 28841389 |
| PQID | 1932850138 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1932850138 pubmed_primary_28841389 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-03-20 20180320 |
| PublicationDateYYYYMMDD | 2018-03-20 |
| PublicationDate_xml | – month: 03 year: 2018 text: 2018-03-20 day: 20 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Journal of clinical oncology |
| PublicationTitleAlternate | J Clin Oncol |
| PublicationYear | 2018 |
| References | 30430025 - J Thorac Dis. 2018 Sep;10(Suppl 26):S3071-S3077 29299414 - Transl Lung Cancer Res. 2017 Dec;6(Suppl 1):S62-S66 29610752 - Ann Transl Med. 2018 Feb;6(3):62 29299413 - Transl Lung Cancer Res. 2017 Dec;6(Suppl 1):S58-S61 29611548 - Ann Transl Med. 2018 Feb;6(3):61 |
| References_xml | – reference: 29299413 - Transl Lung Cancer Res. 2017 Dec;6(Suppl 1):S58-S61 – reference: 29610752 - Ann Transl Med. 2018 Feb;6(3):62 – reference: 29299414 - Transl Lung Cancer Res. 2017 Dec;6(Suppl 1):S62-S66 – reference: 30430025 - J Thorac Dis. 2018 Sep;10(Suppl 26):S3071-S3077 – reference: 29611548 - Ann Transl Med. 2018 Feb;6(3):61 |
| SSID | ssj0014835 |
| Score | 2.6820855 |
| Snippet | Purpose The AURA study ( ClinicalTrials.gov identifier: NCT01802632) included two cohorts of treatment-naïve patients to examine clinical activity and safety... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 841 |
| SubjectTerms | Acrylamides Adult Aged Aged, 80 and over Aniline Compounds Antineoplastic Agents - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - enzymology Carcinoma, Non-Small-Cell Lung - genetics ErbB Receptors - blood ErbB Receptors - genetics Female Humans Lung Neoplasms - drug therapy Lung Neoplasms - enzymology Lung Neoplasms - genetics Male Middle Aged Mutation Piperazines - therapeutic use Progression-Free Survival Protein Kinase Inhibitors - therapeutic use Survival Rate |
| Title | Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/28841389 https://www.proquest.com/docview/1932850138 |
| Volume | 36 |
| WOSCitedRecordID | wos000429062700003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1da8IwFA3bHGMv-3Bf7osMhk9m1rZp0qchohtjatkc-CZJm0BBq7Mq-O9301Z8Ggz20oeWQklv7j3JObkHoUeomY6phEQ6ShNXWhryoICJxx2hqHF2iKzMbIL1enw49INiwy0tZJWbnJgl6mgamj3yugEanBpe7Xn2TYxrlGFXCwuNXVRyAMqYqGbDLYvg8sxg0zi3AoqktKApITDqb62-0XWxJ-Y-Mcq83wFmVmg6x__9xBN0VEBM3Mxj4hTtqKSMDroFiV5G1SBvV72u4cH29FVaw1UcbBtZr8-Q6KfxxOiuk1jiZoo7MUBFAqtXhQcbfTqeatx-6Xzg7jIn9UmQycBWCjcLeQHuwd3PiRiPSUuNx_gd8gtumUfzc_TVaQ9ar6SwZCCh49EFUUzAes3ytA1L20hoZkPp83xJI-X7WkRCNizJfU9GnhV6DelLW1pCK-07NIRUYF-gvWSaqCujqRLc5Z7jMK5czZlUAN20EpxGWrvCr6CHzSiPIOQNjyESNV2mo-04V9Bl_qtGs7w3x8jm3DXc6_Uf3r5BhxAC2QlD27pFJQ0TXt2h_XC1iNP5fRZLcO0F3R9MnNJy |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Osimertinib+As+First-Line+Treatment+of+EGFR+Mutation-Positive+Advanced+Non-Small-Cell+Lung+Cancer&rft.jtitle=Journal+of+clinical+oncology&rft.au=Ramalingam%2C+Suresh+S&rft.au=Yang%2C+James+C-H&rft.au=Lee%2C+Chee+Khoon&rft.au=Kurata%2C+Takayasu&rft.date=2018-03-20&rft.issn=1527-7755&rft.eissn=1527-7755&rft.volume=36&rft.issue=9&rft.spage=841&rft_id=info:doi/10.1200%2FJCO.2017.74.7576&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1527-7755&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1527-7755&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1527-7755&client=summon |